61252-00-4

Usage

Uses

Used in Pharmaceutical Industry:
Benzenepropanoic acid, 4-amino-b-oxo-, ethyl ester is used as a chemical intermediate for the synthesis of various drugs and biologically active compounds. Its role in the production of pharmaceuticals is attributed to its ability to serve as a building block in the creation of new and innovative medications.
Used in Cancer Research and Treatment:
In the field of oncology, Benzenepropanoic acid, 4-amino-b-oxo-, ethyl ester is utilized as an inhibitor of purine nucleoside phosphorylase, an enzyme that plays a critical role in the proliferation of cancer cells. By inhibiting this enzyme, the compound has the potential to disrupt the growth and spread of cancer, making it a valuable asset in cancer research and treatment.
Used in Medicinal Chemistry:
Benzenepropanoic acid, 4-amino-b-oxo-, ethyl ester is employed as a key component in the field of medicinal chemistry, where it contributes to the development of new drugs and therapies. Its unique structure and properties allow researchers to explore its potential in various applications, including the treatment of diseases and the enhancement of existing medications.

InChI:InChI=1/C11H13NO3/c1-2-15-11(14)7-10(13)8-3-5-9(12)6-4-8/h3-6H,2,7,12H2,1H3

Upstream product

• 838-57-3 ethyl 4-nitrobenzoylacetate 

Downstream Products

• 110473-55-7 4-<(methanesulfonyl)amino>-β-oxobenzenepropanoic acid ethyl ester 
• 401935-11-3 ethyl 3-[4-(4-methylphenylsulfonamido)phenyl]-3-oxopropanoate 
• 91958-11-1 ethyl 3-(4-acetamidophenyl)-3-oxopropanoate 
• 888229-72-9 5-(4-amino-phenyl)-2-methyl-2H-pyrazol-3-ol 

Relevant academic research and scientific papers

Discovery of selective SIRT2 inhibitors as therapeutic agents in B-cell lymphoma and other malignancies

Genetic ablation as well as pharmacological inhibition of sirtuin 2 (SIRT2), an NAD+dependent protein deacylase, have therapeutic effects in various cancers and neurodegenerative diseases. Previously, we described the discovery of a dual SIRT1/SIRT2 inhibitor called cambinol (IC50 56 and 59 μM, respectively), which showed cytotoxic activity against cancer cells in vitro and a marked anti-proliferative effect in a Burkitt lymphoma mouse xenograft model. A number of recent studies have shown a protective effect of SIRT1 and SIRT3 in neurodegenerative and metabolic diseases as well as in certain cancers prompting us to initiate a medicinal chemistry effort to develop cambinol-based SIRT2-specific inhibitors devoid of SIRT1 or SIRT3 modulating activity. Here we describe potent cambinol-based SIRT2 inhibitors, several of which show potency of ~600 nM with >300 to >800-fold selectivity over SIRT1 and 3, respectively. In vitro, these inhibitors are found to be toxic to lymphoma and epithelial cancer cell lines. In particular, compounds 55 (IC50 SIRT2 0.25 μM and 25% inhibition at 50 μM against SIRT1 and SIRT3) and 56 (IC50 SIRT2 0.78 μM and 25% inhibition at 50 μM against SIRT1 and SIRT3) showed apoptotic as well as strong anti-proliferative properties against B-cell lymphoma cells.

BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS

Bifunctional compounds that increase uric acid excretion and reduce uric acid production, and monofunctional compounds that either increase uric acid excretion or reduce uric acid production. Methods of using these compounds for reducing uric acid levels

Synthesis of 6-arylisocytosines and their potential for hydrogen bonding interactions

Abstract The synthesis of a number of 6-arylisocytosines, including linked bis-isocytosines, from the reaction of guanidine with β-ketoesters is described. The compounds were investigated for their ability to form hydrogen-bonded structural networks, and for their potential interactions with the telomeric quadruplex forming sequence AGGG(TTAGGG)3.

Synthesis and evaluation of the α-glucosidase inhibitory activity of 3-[4-(phenylsulfonamido)benzoyl]-2H-1-benzopyran-2-one derivatives

In the course of studies directed toward the discovery of novel non-sugar α-glucosidase inhibitors for the treatment of diabetes, a series of 3-[4-(phenylsulfonamido)benzoyl]-2H-1-benzopyran-2-one derivatives was synthesized and evaluated as α-glucosidase inhibitors. Most compounds showed good inhibitory activity with IC50 values ranging from 0.0645?μM to 26.746?μM. 7-Hydroxy-6-methoxy-3-[4-(4-methylphenylsulfonamido)benzoyl]-2H-1-benzopyran-2-one 7u manifested the most potent inhibitory activity with an IC50 value of 0.0645 μM.